<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> and Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) are closely interrelated, and are two of the most common <z:hpo ids='HP_0011010'>chronic</z:hpo>, debilitating diseases worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Surgical approaches to <z:hpo ids='HP_0001824'>weight loss</z:hpo> (bariatric surgery) result in marked improvement of T2DM, however randomized trials directly comparing the efficacy of surgical and medical approaches are lacking </plain></SENT>
<SENT sid="2" pm="."><plain>The Surgical Therapy and Medications Potentially Eradicate <z:mp ids='MP_0002055'>Diabetes</z:mp> Efficiently (STAMPEDE) trial was designed to evaluate the efficacy of two bariatric surgery procedures involving gastric restriction only (laparascopic sleeve gastrectomy) and gastric bypass (Roux-en-Y) to advanced medical therapy in patients with T2DM with modest <z:hpo ids='HP_0001513'>obesity</z:hpo> with BMI of 27-42 kg/m2 </plain></SENT>
<SENT sid="3" pm="."><plain>This single site, prospective, randomized controlled trial will enroll 150 subjects who will be followed </plain></SENT>
<SENT sid="4" pm="."><plain>The primary end point will be the rate of biochemical resolution of T2DM at 1 year as measured by HbA1c &lt; 6% </plain></SENT>
<SENT sid="5" pm="."><plain>The safety and adverse event rates will also be compared between the three arms of the study </plain></SENT>
</text></document>